Page last updated: 2024-10-29

ketanserin and Pulmonary Disease, Chronic Obstructive

ketanserin has been researched along with Pulmonary Disease, Chronic Obstructive in 1 studies

Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.

Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Yang, T1
Wang, H1
Li, Y1
Zeng, Z1
Shen, Y1
Wan, C1
Wu, Y1
Dong, J1
Chen, L1
Wen, F1

Other Studies

1 other study available for ketanserin and Pulmonary Disease, Chronic Obstructive

ArticleYear
Serotonin receptors 5-HTR2A and 5-HTR2B are involved in cigarette smoke-induced airway inflammation, mucus hypersecretion and airway remodeling in mice.
    International immunopharmacology, 2020, Volume: 81

    Topics: Airway Remodeling; Animals; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Humans; Injections

2020